DUTASTERIDE (dutasteride) by Aurobindo Pharma is 5-alpha reductase inhibitors [moa]. Approved for symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for bph-related surgery and 3 more indications. First approved in 2015.
Drug data last refreshed 21h ago
5-alpha Reductase Inhibitors
5-alpha Reductase Inhibitor
Worked on DUTASTERIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil
A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects